BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
KU Leuven
Lovaina, BélgicaPublications in collaboration with researchers from KU Leuven (5)
2016
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477